Cargando…

Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer

We aimed to assess contralateral breast cancer (CBC) risk in patients with ductal carcinoma in situ (DCIS) compared with invasive breast cancer (BC). Women diagnosed with DCIS (N = 28,003) or stage I–III BC (N = 275,836) between 1989 and 2017 were identified from the nationwide Netherlands Cancer Re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giardiello, Daniele, Kramer, Iris, Hooning, Maartje J., Hauptmann, Michael, Lips, Esther H., Sawyer, Elinor, Thompson, Alastair M., de Munck, Linda, Siesling, Sabine, Wesseling, Jelle, Steyerberg, Ewout W., Schmidt, Marjanka K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609533/ https://www.ncbi.nlm.nih.gov/pubmed/33298933 http://dx.doi.org/10.1038/s41523-020-00202-8

Ejemplares similares

Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast
por: van Seijen, Maartje, et al.
Publicado: (2021)

Risk of metachronous contralateral breast cancer in patients with primary invasive lobular breast cancer: Results from a nationwide cohort
por: Akdeniz, Delal, et al.
Publicado: (2022)

Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women
por: Elshof, Lotte E., et al.
Publicado: (2016)

Prediction and clinical utility of a contralateral breast cancer risk model
por: Giardiello, Daniele, et al.
Publicado: (2019)

Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study
por: Akdeniz, Delal, et al.
Publicado: (2021)

PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients
por: Giardiello, Daniele, et al.
Publicado: (2022)

Correction: PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients
por: Giardiello, Daniele, et al.
Publicado: (2022)

Letter to the editor: a response to Ming’s study on machine learning techniques for personalized breast cancer risk prediction
por: Giardiello, Daniele, et al.
Publicado: (2020)

Improved risk estimation of locoregional recurrence, secondary contralateral tumors and distant metastases in early breast cancer: the INFLUENCE 2.0 model
por: Völkel, Vinzenz, et al.
Publicado: (2021)

Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ
por: Almekinders, Mathilde M. M., et al.
Publicado: (2021)

Ductal carcinoma in situ: to treat or not to treat, that is the question
por: van Seijen, Maartje, et al.
Publicado: (2019)

The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study
por: Elshof, Lotte E., et al.
Publicado: (2017)

Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age
por: Drooger, Jan C., et al.
Publicado: (2015)

Coexistence of Granular Cell Tumor and Invasive Ductal Breast Cancer in Contralateral Breasts: A Case Report
por: Di Bonito, Maurizio, et al.
Publicado: (2014)

The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review
por: Alaeikhanehshir, Sena, et al.
Publicado: (2020)

The spectrum of ATM missense variants and their contribution to contralateral breast cancer
por: Broeks, Annegien, et al.
Publicado: (2007)

Impact of the suspension and restart of the Dutch breast cancer screening program on breast cancer incidence and stage during the COVID-19 pandemic
por: Eijkelboom, Anouk H., et al.
Publicado: (2021)

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
por: Groen, Emma J., et al.
Publicado: (2021)

The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands
por: Dinmohamed, Avinash G., et al.
Publicado: (2020)

Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiation
por: van Barele, Mark, et al.
Publicado: (2023)

Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer
por: Lips, Esther H., et al.
Publicado: (2022)

Corrigendum to “The impact of menstruation persistence or recovery after chemotherapy on survival in young patients with hormone receptor negative breast cancer” [Breast 52 (2020) 102–109]
por: van Barele, Mark, et al.
Publicado: (2020)

Concurrent granulomatous mastitis and invasive ductal cancer in contralateral breasts—a case report and review
por: Evans, Jonathan, et al.
Publicado: (2021)

DCIS and LCIS: Are the Risk Factors for Developing In Situ Breast Cancer Different?
por: Timbres, Jasmine, et al.
Publicado: (2023)

The impact of coding germline variants on contralateral breast cancer risk and survival
por: Morra, Anna, et al.
Publicado: (2023)

Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients
por: Sobral-Leite, Marcelo, et al.
Publicado: (2017)

The impact of menstruation persistence or recovery after chemotherapy on survival in young patients with hormone receptor negative breast cancer
por: van Barele, Mark, et al.
Publicado: (2020)

Invasive Micropapillary Carcinoma in Axillary Ectopic Breast and Synchronous Ductal Carcinoma In Situ in the Contralateral Breast
por: Oh, Seung Won, et al.
Publicado: (2017)

Proteomic profiling of extracellular vesicles allows for human breast cancer subtyping
por: Rontogianni, Stamatia, et al.
Publicado: (2019)

Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy
por: Kriege, M, et al.
Publicado: (2014)

Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk
por: Almekinders, Mathilde M., et al.
Publicado: (2022)

A prediction model for underestimation of invasive breast cancer after a biopsy diagnosis of ductal carcinoma in situ: based on 2892 biopsies and 589 invasive cancers
por: Meurs, Claudia J. C., et al.
Publicado: (2018)

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
por: Liefaard, M. C., et al.
Publicado: (2023)

Asymptomatic Incidental Ductal Carcinoma in situ in a Male Breast Presenting with Contralateral Gynecomastia
por: Isley, Laura M., et al.
Publicado: (2012)

Variability in grading of ductal carcinoma in situ among an international group of pathologists
por: van Seijen, Maartje, et al.
Publicado: (2021)

Pathological and Biological Differences Between Screen-Detected and Interval Ductal Carcinoma in situ of the Breast
por: de Roos, Marnix A., et al.
Publicado: (2007)

Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study
por: Mannu, Gurdeep S., et al.
Publicado: (2019)

Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy
por: Vollebergh, Marieke A, et al.
Publicado: (2014)

Tumour-educated platelets for breast cancer detection: biological and technical insights
por: Liefaard, Marte C., et al.
Publicado: (2023)

Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ
por: Elshof, Lotte E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1apfp7hsektovupcb66cnen1sd